Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Eltrombopag> ?p ?o. }
Showing items 1 to 65 of
65
with 100 items per page.
- Eltrombopag abstract "Eltrombopag (rINN, codenamed SB-497115-GR) is a medication that has been developed for conditions that lead to thrombocytopenia (abnormally low platelet counts). It is a small molecule agonist of the c-mpl (TpoR) receptor, which is the physiological target of the hormone thrombopoietin. Eltrombopag was discovered as a result of research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals. Designated an orphan drug in the USA and European Union, it is being manufactured and marketed by GlaxoSmithKline under the trade name Promacta in the USA and will be marketed as Revolade in the EU. Eltrombopag was approved by the U.S. Food and Drug Administration on November 20, 2008. Eltrombopag received FDA breakthrough treatment designation in February 2014 for patients with aplastic anemia for which immunosupression has not been successful. It has been shown to produce a trilineage hematopoesis in some patients with aplastic anemia, resulting in increased platelet counts, along with red and white blood cell counts.".
- Eltrombopag atcPrefix "B02".
- Eltrombopag atcSuffix "BX05".
- Eltrombopag casNumber "496775-61-2".
- Eltrombopag casSupplemental "(olamine)".
- Eltrombopag fdaUniiCode "S56D65XJ9G".
- Eltrombopag iupacName "3'-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazino}-2'-hydroxy-3-biphenylcarboxylic acid".
- Eltrombopag pubchem "9846180".
- Eltrombopag thumbnail Eltrombopag.svg?width=300.
- Eltrombopag wikiPageID "14488084".
- Eltrombopag wikiPageRevisionID "604256862".
- Eltrombopag atcPrefix "B02".
- Eltrombopag atcSuffix "BX05".
- Eltrombopag c "25".
- Eltrombopag casNumber "496775".
- Eltrombopag chembl "461101".
- Eltrombopag chemspiderid "21106301".
- Eltrombopag h "22".
- Eltrombopag hasPhotoCollection Eltrombopag.
- Eltrombopag inchi "1".
- Eltrombopag inchikey "XDXWLKQMMKQXPV-HPNDGRJYBX".
- Eltrombopag iupacName "3".
- Eltrombopag licenceUs "Eltrombopag".
- Eltrombopag medlineplus "a609011".
- Eltrombopag molecularWeight "442.467".
- Eltrombopag n "4".
- Eltrombopag o "4".
- Eltrombopag pubchem "9846180".
- Eltrombopag routesOfAdministration "Oral".
- Eltrombopag smiles "CC1=CC".
- Eltrombopag stdinchi "1".
- Eltrombopag stdinchikey "XDXWLKQMMKQXPV-HPNDGRJYSA-N".
- Eltrombopag unii "S56D65XJ9G".
- Eltrombopag verifiedfields "changed".
- Eltrombopag verifiedrevid "461093150".
- Eltrombopag width "200".
- Eltrombopag subject Category:Drugs.
- Eltrombopag subject Category:Orphan_drugs.
- Eltrombopag type Agent114778436.
- Eltrombopag type CausalAgent100007347.
- Eltrombopag type Drug103247620.
- Eltrombopag type Drugs.
- Eltrombopag type Matter100020827.
- Eltrombopag type OrphanDrugs.
- Eltrombopag type PhysicalEntity100001930.
- Eltrombopag type Substance100020090.
- Eltrombopag type Drug.
- Eltrombopag type DrugProduct.
- Eltrombopag type FunctionalSubstance.
- Eltrombopag comment "Eltrombopag (rINN, codenamed SB-497115-GR) is a medication that has been developed for conditions that lead to thrombocytopenia (abnormally low platelet counts). It is a small molecule agonist of the c-mpl (TpoR) receptor, which is the physiological target of the hormone thrombopoietin. Eltrombopag was discovered as a result of research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals.".
- Eltrombopag label "Eltrombopag".
- Eltrombopag label "Eltrombopag".
- Eltrombopag label "Eltrombopag".
- Eltrombopag label "Eltrombopag".
- Eltrombopag sameAs Eltrombopag.
- Eltrombopag sameAs Eltrombopag.
- Eltrombopag sameAs Eltrombopag.
- Eltrombopag sameAs m.03d51s1.
- Eltrombopag sameAs Q411588.
- Eltrombopag sameAs Q411588.
- Eltrombopag sameAs ELTROMBOPAG.
- Eltrombopag sameAs Eltrombopag.
- Eltrombopag wasDerivedFrom Eltrombopag?oldid=604256862.
- Eltrombopag depiction Eltrombopag.svg.
- Eltrombopag isPrimaryTopicOf Eltrombopag.
